| 词条 | Erdafitinib |
| 释义 |
| drug_name = | INN = | type = | IUPAC_name = N′-(3,5-Dimethoxyphenyl)-N′-[3-(1-methylpyrazol-4-yl)quinoxalin-6-yl]-N-propan-2-ylethane-1,2-diamine | image = Erdafitinib.svg | alt = | caption = | pronounce = | tradename = | Drugs.com = | MedlinePlus = | pregnancy_AU = | pregnancy_AU_comment = | pregnancy_US = | pregnancy_category= | routes_of_administration = | legal_AU = | legal_AU_comment = | legal_BR = | legal_BR_comment = | legal_CA = | legal_DE = | legal_NZ = | legal_UK = | legal_US = | legal_UN = | legal_status = | bioavailability = | protein_bound = | metabolism = | metabolites = | onset = | elimination_half-life = | duration_of_action = | excretion = | CAS_number = 1346242-81-6 | class = | ATCvet = | ATC_prefix = | ATC_suffix = | PubChem = 67462786 | DrugBank = | UNII = 890E37NHMV | KEGG = D10927 | synonyms = JNJ-42756493 | C=25|H=30|N=6|O=2 | smiles = CC(C)NCCN(C1=CC2=NC(=CN=C2C=C1)C3=CN(N=C3)C)C4=CC(=CC(=C4)OC)OC }} Erdafitinib[1] is an experimental small molecule inhibitor of FGFR being investigated for use in treating cancer. FGFRs are a subset of tyrosine kinases which are unregulated in some tumors and influence tumor cell differentiation, proliferation, angiogenesis, and cell survival.[2] Astex Pharmaceuticals discovered the drug and licensed it to Janssen Pharmaceuticals for further development. Erdafitinib is being evaluated for safety and efficacy in phase II clinical trials for cholangiocarcinoma, gastric cancer, non-small cell lung cancer, and esophageal cancer.[3] In March 2018, erdafitinib was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for treatment of urothelial cancer, which should expedite its development and regulatory review.[2] References1. ^https://searchusan.ama-assn.org/usan/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Ferdafitinib.pdf 2. ^1 {{cite web|url=https://www.jnj.com/media-center/press-releases/janssen-announces-us-fda-breakthrough-therapy-designation-for-erdafitinib-in-the-treatment-of-metastatic-urothelial-cancer|title=Janssen Announces U.S. FDA Breakthrough Therapy Designation for Erdafitinib in the Treatment of Metastatic Urothelial Cancer - Johnson & Johnson|website=www.jnj.com}} 3. ^{{cite web|url=http://adisinsight.springer.com/drugs/800036975|title=Erdafitinib - Janssen Pharmaceutica - AdisInsight|website=adisinsight.springer.com}} 4 : Experimental cancer drugs|Quinoxalines|Protein kinase inhibitors|Pyrazoles |
| 随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。